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Abstract: Bone remodeling is tightly regulated by a cross-talk between bone-forming osteoblasts and
bone-resorbing osteoclasts. Osteoblasts and osteoclasts communicate with each other to regulate
cellular behavior, survival and differentiation through direct cell-to-cell contact or through secretory
proteins. A direct interaction between osteoblasts and osteoclasts allows bidirectional transduction of
activation signals through EFNB2-EPHB4, FASL-FAS or SEMA3A-NRP1, regulating differentiation
and survival of osteoblasts or osteoclasts. Alternatively, osteoblasts produce a range of different
secretory molecules, including M-CSF, RANKL/OPG, WNT5A, and WNT16, that promote or suppress
osteoclast differentiation and development. Osteoclasts also influence osteoblast formation and
differentiation through secretion of soluble factors, including S1P, SEMA4D, CTHRC1 and C3. Here we
review the current knowledge regarding membrane bound- and soluble factors governing cross-talk
between osteoblasts and osteoclasts.
Keywords: bone; osteoblast; osteoclast; bone remodeling
1. Introduction
Bone is a dynamic tissue that remodels continuously throughout life, providing mechanical
support for stature and locomotion and protecting vital organs such as bone marrow and the brain [1].
Bone also functions as a reservoir for calcium and phosphate. Continuous remodeling is required to
preserve both of these critical functions by preventing accumulation of bone damage and maintaining
both the mechanical strength of bone and calcium homeostasis [2,3].
Bone remodeling is a process in which old or damaged bone is removed by osteoclasts and
replaced with new bone formed by osteoblasts. Osteoclasts, bone-resorbing cells, originate from
hematopoietic stem cells (HSCs) [4–8] and degrade bone via secretion of acid and proteolytic
enzymes, such as cathepsin K (CTSK), that dissolve collagen and other matrix proteins during
bone resorption [9,10]. Osteoblasts, bone-forming cells, arise from the commitment of mesenchymal
precursors to osteoprogenitor lineages through the sequential action of transcriptional factors and
terminally differentiate into osteocytes [11–14]. Osteoblasts produce extracellular proteins, including
osteocalcin, alkaline phosphatase and type I collagen, the latter of which makes up over 90% of bone
matrix protein. The extracellular matrix is first secreted as unmineralized osteoid and subsequently
mineralized through the accumulation of calcium phosphate in the form of hydroxyapatite [15].
The sequential strategies of osteoclastogenesis and osteoblastogenesis are shown in Figure 1.
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Figure 1. Strategies of osteoclastogenesis and osteoblastogenesis. (a) Osteoclastogenesis. Osteoclasts 
are tissue-specific macrophages derived from hematopoietic stem cells. In the presence of M-CSF, 
hematopoietic stem cells are committed to macrophage colony-forming units (CFU-M), the common 
precursor cells of macrophages and osteoclasts. When activated by the RANKL-RANK signal, CFU-
M is further differentiated into mononucleated osteoclasts and subsequently fuse to become 
multinucleated osteoclasts. Multinucleated osteoclasts are fully matured upon a cognate interaction 
with osteoblasts and resorb bone matrix by secreting acids (H+), proteases (e.g., CTSK) and matrix 
metalloproteinases (MMPs) when they have a tight junction between the bone surface and basal 
membrane of osteoclasts to form a sealed compartment and then osteoclasts. (b) Osteoblastogenesis. 
Osteoblasts are derived from multipotent mesenchymal precursors and they are committed to 
osteoprogenitors and further differentiated into osteoblastic lineage through the expression of 
transcription factors RUNX2 and Osterix. They are continued to differentiation into matrix-producing 
mature osteoblasts and these cells have different fates: apoptosis, bone lining cells or osteocytes. A 
subpopulation of mature osteoblasts is surrounded by unmineralized osteoid and further 
differentiated into osteocytes, terminally differentiated bone cells in mineralized bone. 
Bone remodeling is traditionally considered to be composed of four sequential phases [16]: the 
activation phase when osteoclast progenitors are recruited to damaged bone surface; resorption 
phase when mature osteoclasts resorb damaged bone; reversal phase when osteoclasts die and 
osteoblast progenitors are recruited; formation phase when mature osteoblasts produce new bone 
matrix (osteoid) and this matrix is mineralized [17,18]. Almost all new bone formation is observed in 
areas with previous resorption and in distinct anatomical structures called basic multicellular units 
(BMUs) [19]. The balance between osteoblast-mediated bone formation and osteoclast-mediated bone 
resorption is tightly regulated without a major alteration in a net bone mass or mechanical strength 
under homeostatic conditions [2]. However, dysregulation of this balance results in abnormal bone 
Figure 1. Strategies of osteoclastogenesis and osteoblastogenesis. (a) Osteoclastogenesis. Osteoclasts
are tissue-specific macrophages derived from hematopoietic stem cells. In the presence of M-CSF,
hematopoietic stem cells are committed to macrophage colony-forming units (CFU-M), the common
precursor cells of macrophages and osteoclasts. When activated by the RANKL-RANK signal, CFU-M is
further differentiated into mononucleated osteoclasts and subsequently fuse to become multinucleated
osteoclasts. Multinucleated osteoclasts are fully matured upon a cognate interaction with osteoblasts
and resorb bone matrix by secreting acids (H+), proteases (e.g., CTSK) and matrix metalloproteinases
(MMPs) when they have a tight junction between the bone surface and basal membrane of osteoclasts
to form a sealed compartment and then osteoclasts. (b) Osteoblastogenesis. Osteoblasts are derived
from multipotent mesenchymal precursors and they are committed to osteoprogenitors and further
differentiated into osteoblastic lineage through the expression of transcription factors RUNX2 and
Osterix. They are continued to differentiation into matrix-producing mature osteoblasts and these cells
have different fates: apoptosis, bone lining c lls or osteocytes. A subpopulation of mature osteoblasts is
surr unded by unmineralized osteoid and further differ ntiated into osteocyt s, terminally differentiated
bone cells in mineralized bone.
Bone remodeling is traditionally considered to be composed f four sequential phases [16]:
the ctivation phase when steoclast progenitors a ecruited to damaged bone surface; resorption
phase when mature osteoclasts resorb damaged bone; reversal phase when osteoclasts die and
osteoblast progenitors are recruited; formation phase when mature osteoblasts produce new bone
matrix (osteoid) and this matrix is mineralized [17,18]. Almost all new bone formation is observed in
areas with previous resorption and in distinct anatomical structures called basic multicellular units
(BMUs) [19]. The balanc b tween steoblast-mediated b ne form tion and osteoclast-mediat d
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bone resorption is tightly regulated without a major alteration in a net bone mass or mechanical
strength under homeostatic conditions [2]. However, dysregulation of this balance results in abnormal
bone remodeling, resulting in both postmenopausal and secondary forms of osteoporosis, such as
diabetes-associated and glucocorticoid-induced osteoporosis [20–22]. In addition to improving
understanding of the bone resorption and formation phases, a more detailed study on the reversal
phase might be necessary as reversal step dysfunction is associated with pathologic bone loss [23,24].
In this review, we illustrate the key mediators that control the cross-talk between osteoblasts and
osteoclasts through cell–cell contact or secretory factors (Figure 2).
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are essential for fine-tuning of bone remodeling during bone homeostasis. (1) Osteoblasts and 
osteoclasts have direct contacts through the interactions between EFNB2-EPHB4, FAS-FASL and 
NRP1-SEMA3A to regulate cell proliferation, differentiation, and survival. (2) Osteoclast-mediated 
bone resorption releases TGF-β and IGF-1 from bone matrix to induce osteoblast-mediated bone 
formation. (3) Osteoblasts secrete M-CSF, RANKL, WNT5A that promote osteoclast formation and 
development and OPG and WNT16 that inhibit osteoclast activity. Conversely, osteoclasts secrete 
S1P, CTHRC1 and C3 that promote osteoblast differentiation and SEMA4D that suppresses 
osteoblasts differentiation. 
The factors which control osteoblast–osteoclast communication will be reviewed in cellular 
levels, mainly in genetic mouse models. 
2. Membrane-Bound Mediators of Cell-to-Cell Communication 
2.1. EFNB2 (Ephrin B2)-EPHB4 
During bone remodeling, osteoblasts and osteoclasts communicate through cell-to-cell direct 
contact [25]. This interaction can be mediated by Ephrin signaling, which is critical for the 
bidirectional communication between osteoclasts and osteoblasts [26–28]. Cell-surface molecules 
Ephrin B (B1∼B3) bind to their cognate tyrosine kinase receptors EPHB (B1∼B6). The Ephrin B family 
consists of transmembrane proteins with cytoplasmic domains and its interaction with EPHB-
expressing cells mediates bidirectional signal transduction [29]. Ephrin B2 (EFNB2), expressed on the 
cell surface of osteoclasts, binds to osteoblast surface molecule EPHB4. Reverse signaling (osteoblast 
to osteoclast) is initiated by EPHB4-mediated activation of EFNB2 and suppresses osteoclast 
differentiation by blocking the osteoclastogenic C-FOS/NFATC1 cascade. In forward signaling 
Figure 2. Key mediators of osteoblast-osteoclast interaction. Osteoblast-osteoclast communications are
essential for fine-tuning of bone remodeling during bone homeostasis. (1) Osteoblasts and osteoclasts
have direct contacts through the interactions between EFNB2-EPHB4, FAS-FASL and NRP1-SEMA3A to
regulate cell proliferation, differentiation, and survival. (2) Osteoclast-mediated bone resorption releases
TGF-β and IGF-1 from bone matrix to induce osteoblast-mediated bone formation. (3) Osteoblasts
secrete M-CSF, RANKL, WNT5A that promote osteoclast formation and development and OPG and
WNT16 that inhibit osteoclast activity. Conversely, osteoclasts secrete S1P, CTHRC1 and C3 that
promote osteoblast differentiation and SEMA4D that suppresses osteoblasts differentiation.
The factors which control osteoblast–osteoclast communication will be reviewed in cellular levels,
mainly in genetic mouse models.
2. Membrane-Bound Mediators of Cell-to-Cell Communication
2.1. EFNB2 (Ephrin B2)-EPHB4
During bone remodeling, osteoblasts and osteoclasts communicate through cell-to-cell direct
contact [25]. This interaction can be mediated by Ephrin signaling, which is critical for the bidirectional
communication between osteoclasts and osteoblasts [26–28]. Cell-surface molecules Ephrin B (B1∼B3)
bind to their cognate tyrosine kinase receptors EPHB (B1∼B6). The Ephrin B family consists of
transmembrane proteins with cytoplasmic domains and its interaction with EPHB-expressing cells
mediates bidirectional signal transduction [29]. Ephrin B2 (EFNB2), expressed on the cell surface of
osteoclasts, binds to osteoblast surface molecule EPHB4. Reverse signaling (osteoblast to osteoclast)
is initiated by EPHB4-mediated activation of EFNB2 and suppresses osteoclast differentiation by
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blocking the osteoclastogenic C-FOS/NFATC1 cascade. In forward signaling (osteoclast to osteoblast),
EFNB2-mediated activation of EPHB4 promotes osteoblast differentiation and suppresses apoptosis [30].
Similarly, overexpression of EPHB4 in osteoblasts increases bone mass in a transgenic mouse model [26].
2.2. FAS Ligand (FASL)-FAS
FAS (also called as APO-1 or CD95) is a death domain–containing member of the tumor necrosis
factor receptor (TNFR) superfamily. FAS ligand (FASL or CD95L) plays a central role in the physiological
regulation of apoptosis of FAS-expressing cells, which is associated with various disease processes,
such as tumorigenesis and several auto-immune diseases [31,32]. Deficiency of estrogen is closely linked
to postmenopausal osteoporosis, and estrogen has been known to induce osteoclast apoptosis [33,34].
In line with the effects of estrogen on osteoclast apoptosis, further study demonstrated that FAS-FASL
signaling is involved in estrogen-induced osteoclast apoptosis [35]. Upregulated expression of FASL
in osteoblasts by estrogen results in apoptosis of pre-osteoclasts, suggests that a paracrine signal
emanating from osteoblasts plays an important role in the protective effects of estrogen in bone.
Additional study has demonstrated that conditional knockout of FASL in osteoblasts increases the
number and activity of osteoclasts, resulting in reduced bone mass [36]. Similarly, osteoblasts from
ovariectomized (estrogen-deficient) mice exhibit a decrease in FASL expression, resulting in reduced
osteoclast apoptosis and increased bone resorption.
2.3. Semaphorin 3A (SEMA3A)-NRP1
Semaphorins were originally identified as axon guidance factors involved in the development
of neuronal system, but they also play a role in various physiological processes including
osteoblast-osteoclast interactions [37–39]. Semaphorin 3A (SEMA3A) is the first semaphorin family
member identified in vertebrates and ubiquitously expressed in many types of tissue, including
brain and bone. While SEMA3A participates in the development of major structures of the nervous
system [40], many studies suggest that SEMA3A also plays a key role in both bone modeling and
remodeling [40–42]. In particular, sensory neuron-derived SEMA3A is necessary for normal bone
formation in vivo [42]. Additionally, SEMA3A, produced by osteoblast lineage cells, functions as
a potent osteoprotective factor by synchronously inhibiting bone resorption and promoting bone
formation [38]. High levels of SEMA3A were detected in the conditioned media of osteoprotegerin
(OPG, anti-osteoclastogenic factor)-deficient osteoblasts, and its binding to neuropilin-1 (NRP1)
inhibits RANKL-induced osteoclast differentiation, and promotes osteoblast differentiation through
the WNT/β-catenin pathway.
3. Soluble Factors Released from Osteoblasts
3.1. Macrophage Colony-Stimulating Factor (M-CSF)
M-CSF (also called as CSF1) is a hematopoietic growth factor that allows for survival, proliferation,
differentiation, and mobility of mononuclear phagocyte lineages, including osteoclasts [43,44]. M-CSF,
secreted from osteoblasts and bone marrow stromal cells, binds to its cognate receptor C-FMS on
the surface of osteoclasts and monocytes/macrophages [45]. Osteopetrotic (op/op) mice where a
thymidine insertion in the Csf1 gene resulted in M-CSF deficiency show decreased numbers of
macrophages and osteoclasts at a young age. However, these phenotypes disappear during aging.
Injection of recombinant M-CSF or production of soluble M-CSF in osteoblasts increases osteoclast
numbers and rescues osteopetrotic phenotypes in op/op mice, demonstrating that M-CSF is crucial for
osteoclast formation at least in young mice, but does not exclude the existence of M-CSF-independent
compensatory mechanisms.
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3.2. Receptor Activator of NF-κB (Nuclear Factor-Kappa B) Ligand (RANKL)
RANKL is also called osteoclast differentiation factor (ODF), TNF ligand superfamily member
11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), and OPG ligand (OPGL) [46,47].
RANKL is highly expressed in osteoblasts, osteocytes, activated T lymphocytes, and lymph
nodes [48–50]. RANKL binds to its cognate receptor, receptor activator of NF-κB (RANK) on the surface
of osteoclasts and osteoclast precursors, leading to osteoclast differentiation, fusion, and activation [6,51].
Mice deficient in Tnfrsf11a (RANK) or Tnfsf11 (RANKL) are phenocopies of one another, indicating the
essential role of this RANKL/RANK signaling axis in bone remodeling [48,51]. Deletion of RANKL in
mice results in severe osteopetrosis due to absence of osteoclasts, whereas overexpression of soluble
RANKL leads to severe osteoporosis [48,52]. Accordingly, blocking RANKL signaling has been
proposed as a promising therapeutic target for osteoporotic bone loss and related skeletal disorders.
3.3. Osteoprotegerin (OPG)
OPG is also known as osteoclastogenesis inhibitory factor (OCIF) and TNF receptor superfamily
member 11B (TNFRSF11B) [47,53,54]. OPG was identified as a secreted glycoprotein synthesized by
many types of cells, including osteoblasts, lung- or liver-residing cells, and B lymphocytes in the
bone marrow [53–55]. Overexpression of OPG results in profound osteopetrosis due to inhibition
of osteoclast formation, whereas Tnfrsf11b (OPG)—deficient mice exhibit rapid postnatal bone loss
and severe bone porosity due to an increased osteoclast development [53,56]. OPG is considered to
function as a decoy receptor binding to RANKL, negatively regulating osteoclast differentiation and
activation by blocking the RANKL-RANK interaction [6,57].
3.4. WNT5A
The WNT pathway is crucial for the maintenance of bone homeostasis by regulating
osteoblastogenesis and osteoclastogenesis through both β-catenin-dependent (canonical) and
-independent (noncanonical) pathways [58]. A noncanonical WNT ligand, WNT5A, is highly expressed
in osteoblast-lineage cells and binds to its cognate receptor, receptor tyrosine kinase-like orphan
receptor 2 (ROR2), on the surface of osteoclasts [59]. Heterozygous deletion of Wnt5a or Ror2 in mice
resulted in impaired development of bone marrow-derived monocytes (BMM) to mature osteoclasts.
Corresponding defects in osteoclastogenesis were also observed in mice with osteoblast-specific deletion
of Wnt5a or osteoclast-specific deletion of Ror2. WNT5A enhances RANKL-induced osteoclastogenesis
by upregulating RANK expression in osteoclasts via activation of the Jun–N-terminal kinase (JNK)
MAPK pathway.
3.5. WNT16
The WNT16 locus is closely associated with bone mineral density (BMD), cortical bone thickness,
and fracture risk in humans [60–62]. WNT16 is highly expressed in osteoblast-residing cortical bone,
but little to no expression is detected in osteoclasts [63]. Global deletion of Wnt16 results in a specific
decrease in cortical bone mass and an increase in cortical porosity, along with spontaneous fractures
where there is no alteration in trabecular bone. WNT16 suppresses osteoclastogenesis in both a
direct and indirect manner. In addition to direct inhibition of osteoclastogenesis via the noncanonical
JNK MAPK pathway, WNT16-induced phosphorylation of JUN upregulates expression of OPG in
osteoblasts, providing a direct mechanism to suppress osteoclastogenesis. Osteoblast-specific deletion
of Wnt16 in mice phenocopies mice with its global deletion, suggesting osteoblasts are a primary
source of WNT16, with an impact on cortical bone and skeletal integrity. Table 1 provides a list of
osteoblast-derived factors that regulate osteoclasts.
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Table 1. Summary of the effect of osteoblast-derived factors on osteoclast behavior.
Osteoblast-Derived Factor Mode of Action Influences on Osteoclasts References
EFNB2 Membrane-bound Inhibits osteoclastogenesis [26]
FASL Membrane-bound Induces osteoclast apoptosis [36]
SEMA3A Membrane-bound Inhibits RANKL-inducedosteoclastogenesis [38]
M-CSF Secreted Promotes proliferation andsurvival of osteoclast precursor [45]
RANKL Membrane-bound andsecreted
Promotes osteoclast
differentiation and activation [6,51]
OPG Secreted Inhibits osteoclastogenesis [6,57]
WNT5A Secreted Promotes osteoclastogenesis [58]
WNT16 Secreted Inhibits osteoclastogenesis [63]
4. Soluble Factors Released from Osteoclasts
4.1. Sphingosine 1 Phosphate (S1P)
Sphingosine kinase (SPHK), expressed in osteoclasts, phosphorylates sphingosine to generate
sphingosine 1 phosphate (S1P) promotes osteoblastogenesis [64,65]. S1P production is enhanced
in osteoclast precursors upon RANKL stimulation and S1P binds to S1P receptor on the surface of
osteoblasts, resulting in increased osteoblast migration and survival. Subsequently, S1P-activated
osteoblasts upregulate RANKL expression, augmenting osteoclastogenesis [66]. Further study has
demonstrated that osteoclast-specific deletion of Ctsk (cathepsin K), the lysosomal cysteine protease
that degrades type 1 collagen and matrix proteins during bone resorption showed enhanced bone
formation by increasing S1P production from osteoclasts [65,67].
4.2. Semaphorin 4D (SEMA4D)
SEMA4D is an axon guidance molecule that is also expressed in osteoclasts. Osteoclast-derived
SEMA4D binds to Plexin-B1 (PLXNB1) on the surface of osteoblasts, suppressing osteoblast
differentiation [39]. Mice lacking Sema4d show high bone mass with increased bone forming activity
and enhanced bone strength. Plxnb1-deficient mice also show similar bone phenotypes to those seen in
Sema4d-deficient mice, suggesting that SEMA4D and PLXNB1 are in the same pathway. Mechanistically,
binding of SEMA4D to PLXNB1 activates small GTPase RHOA and subsequently suppresses osteoblast
differentiation through attenuation of insulin-like growth factor-1 (IGF-1) signaling. Administration
of an anti-SEMA4D antibody prevents bone loss in a mouse model of postmenopausal osteoporosis
and promotes bone formation without affecting osteoclast-mediated bone resorption, suggesting that
SEMA4D is a potential therapeutic target for osteoporosis or other low bone mass disorders [68].
4.3. Collagen Triple Helix Repeat Containing 1 (CTHRC1)
CTHRC1 is a soluble protein released from mature osteoclasts that targets stromal cells to
induce osteoblast differentiation [69]. Cthrc1 expression is upregulated when mature osteoclasts
contact hydroxyapatite and calcium. Although the CTHRC1 receptor in the osteoblast has not yet been
identified, recombinant CTHRC1 can induce recruitment of stromal cells and osteoblastic differentiation,
promoting bone formation. In a line with this, osteoclast-specific deletion of Cthrc1 results in low bone
mass with reduced bone formation.
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4.4. Complement Component C (C3)
Osteoclast-derived C3 is cleaved to C3a that induces osteoblastogenesis [70]. Expression of
C3 is upregulated during osteoclastogenesis and a C3a receptor (C3AR) antagonist blunts the
osteogenic activity of osteoclast-derived conditioned medium, while a C3AR agonist promotes
osteoblast differentiation. C3 expression in bone is markedly upregulated in the setting of ovariectomy
(OVX)-induced osteoporosis, or when administered with RANKL. In these settings, a C3AR antagonist
attenuates bone formation activity, accelerating bone loss.
4.5. Other Factors
WNT10B activates the canonical WNT signaling pathway to promote osteoblast differentiation [71].
Osteocalcin promoter-driven expression of Wnt10b in osteoblasts increases bone mineral density and
trabecular bone volume and number, whereas Wnt10b-deficient mice show a decrease in trabecular
bone mass and serum levels of osteocalcin [71,72]. Additionally, osteoclast-derived WNT10B increases
mineralization of human mesenchymal stromal cells, which suppress the presence of recombinant DKK1
(dickkopf WNT signaling pathway inhibitor 1), a WNT antagonist [65]. BMP6 in osteoclast-conditioned
media induces migration and mineralization of human mesenchymal stromal cells, suggesting it as a
coupling factor between osteoclasts and osteoblasts [65]. Finally, vesicular RANK has been considered
as a coupling factor [73]. Vesicular RANK secreted from osteoclasts binds to osteoblastic RANKL
and promotes osteoblast differentiation and bone formation by RANKL reverse signaling. RANKL is
initially produced as transmembrane protein and cleaved by protease to yield a soluble form (sRANKL)
and this sRANKL is required for osteoclast formation in cancellous bone as the skeleton matures [74].
Mostly, the membrane-bound form of RANKL is sufficient for osteoclast formation in developing
skeleton. Accordingly, vesicular RANK might have different acting mechanism during osteoblast
differentiation and bone development. Table 2 provides a list of osteoclasts-derived factors to influence
on osteoblasts behavior.
Table 2. Summary of effects of osteoclast-derived factors on osteoblasts.






S1P Secreted Promotes osteoblast migrationand survival [64,65]
SEMA4D Secreted Suppresses osteoblastogenesis [39]
CTHRC1 Secreted Recruits stromal cells andinduces osteoblastogenesis [69]
C3 Secreted Promotes osteoblastogenesis [70]
WNT10B Secreted Promotes osteoblastogenesis [71,72]
Vesicular RANK Secreted Promotes osteoblastogenesis [73]
5. Matrix-Derived Coupling Factors by Bone Resorption
5.1. Transforming Growth Factor β1 (TGF-β1)
TGF-β1, one of the most abundant proteins in the bone matrix, contributes to bone remodeling
through regulation of both osteoblasts and osteoclasts. In the bone matrix, TGF-β1 is non-covalently
bound to the latency-associated protein (LAP), keeping it in latent state by masking the receptor-binding
domains of the TGF-β1 [75,76]. Accordingly, TGF-β1 stays at an inactive state in bone matrix and is
released from bone matrix in response to osteoclastic bone resorption [77]. Active TGF-β1 recruits bone
mesenchymal lineage cells to resorptive surfaces and differentiates them into bone-forming osteoblasts.
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5.2. Insulin-Like Growth Factor Type 1 (IGF-1)
IGF-1 is another growth factor deposited in the bone matrix, bound to insulin-like growth
factor-binding protein (IGFBP) [78,79]. IGF-1 released from bone matrix is activated by acid pH during
osteoclastic bone resorption [80]. Bone matrix-derived IGF-1 was found to promote osteogenesis
through activation of mammalian target of rapamycin (mTOR) in osteoblast lineage cells [81]. Of note,
IGF-1 concentration in the bone matrix is lower in aged rats than in young rats, suggesting a
correspondence between bone volume and IGF-1 levels.
6. Impact of Therapeutic Agents on Osteoblast-Osteoclast Interactions
Despite there being many factors identified that regulate osteoblast-osteoclast interactions,
currently very few of these pathways have resulted in approved therapeutics for the treatment of
skeletal disorders. However, osteoblast–osteoclast interactions have played a powerful role in shaping
the action of all currently approved drugs acting on the skeleton, including often imposing limitations
on the activities of these agents. Most anti-resorptive agents inhibiting osteoclast formation and
activity simultaneously suppress bone formation, whereas the activity of anabolic agents inducing
bone formation are similarly tempered by simultaneously increasing bone resorption.
Denosumab is a humanized monoclonal antibody that binds RANKL and acts as an OPG-like
RANK decoy receptor, disrupting the RANKL-RANK interaction and osteoclast differentiation,
function, and survival, leading to a decrease in bone resorption. In patients, biannual administration of
Denosumab increases bone density, and reduces the risk of vertebral, nonvertebral, and hip fractures [82].
However, as expected, inhibiting osteoclast formation by blocking RANKL-RANK signaling pathway
results in reduction of osteoclast-derived coupling factors that induce osteoblast-mediated bone
formation. Denosumab leads to an immediate and sustained decrease in markers of bone resorption
such as urinary N-telopeptide (NTX) along with a delayed reduction in markers of bone formation,
such as serum bone specific alkaline phosphatase (BSAP) [83,84].
Odanacatib, a selective cathepsin K (CTSK) inhibitor, suppresses osteoclast-mediated bone
resorption [85,86]. CTSK is a cysteine proteinase, abundantly expressed in activated osteoclasts and
secreted to extracellular space that cleaves the N-telopeptide of collagen [87]. CTSK mutation in
humans causes pycnodysostosis, a rare skeletal dysplasia, characterized by short stature, an increase in
the bone density of long bones, acroosteolysis of distal phalangers and skull deformities [88]. Despite
the high bone mass phenotype, patients with pycnodysostosis suffer from bone fragility with a high
incidence of pathological fractures [89]. Odanacatib has received a lot of attention as a potential
osteoporosis drug since it inhibits osteoclast activity and function, rather than osteoclast generation,
resulting in prevention of bone resorption with more modest overall effects on the ability of osteoblasts
to form bone than most other anti-resorptive agents. It still remains unclear whether these effects reflect
functional blockade of osteoclast-driven coupling processes or whether CTSK inhibition may have
direct effects on CTSK-expressing periosteal mesenchymal progenitors [90,91]. Although odanacatib
was highly effective in reducing fractures of postmenopausal women in clinical phase-3, its further
development was discontinued due to concerns regarding risk of cerebrovascular events [92].
Parathyroid hormone (PTH), a bone anabolic agent, is normally secreted by the parathyroid
glands and contributes to the maintenance of calcium homeostasis through its direct actions on bone
cells. Intermittent PTH administration increases bone mass by recruiting mesenchymal stromal
cells into osteoblast lineage and promoting the differentiation of osteoprogenitors into mature
osteoblast [93,94]. Also, PTH downregulates sclerostin (SOST) expression from osteocytes, leading to a
favorable environment for osteoblast differentiation and function through enhanced WNT signaling
pathway [95,96]. However, continuous treatment results in an increase in net bone resorption due to
increases in RANKL and decreases in the RANKL decoy receptor, OPG, in osteoblasts and osteocytes [97].
As seen in each of these examples, one of the most fundamental and enduring challenges in developing
increasingly effective skeletal therapeutics is overcoming the osteoblast/osteoclast interaction effects
that often blunt the activity of both anti-resorptive and anabolic drugs.
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7. Conclusions and Future Perspectives
In this review, we provide the current knowledge of osteoblast-osteoclast communication in
preserving bone homeostasis. Although multiple cells including osteocytes, chondrocytes, skeletal
stem cells, endothelial cells, and immune cells play a role in controlling bone homeostasis, eventually
they drive bone remodeling through the regulation of osteoblasts or osteoclasts. Accordingly, a broader
understanding of the cell types regulating bone remodeling extending beyond osteoblast–osteoclast
interactions will bring more insights and greater opportunities to develop therapeutics for skeletal
disorders, including osteoporotic bone loss.
Traditionally, bone remodeling has been suggested as a sequential stepwise process, with initial
osteoclast-mediated bone resorption followed by osteoblast-mediated bone formation [98]. However,
osteoclast activity is not always restricted to specialized remodeling sites, and bone resorption is not
always followed by osteoblast repopulation in the setting of pathologic skeletal disorders, such as
inflammatory bone loss. Moreover, osteoclast-derived coupling can occur independent of bone
resorption activity. Therefore, the spatial and temporal regulation of the bone remodeling process
requires further elucidation, including further identification of the communication factors regulating
osteoclast/osteoblast communication in physiologic and pathologic contexts.
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